Given DHA inhibits PD-L1 expression and PD-L1 level represents the potential biomarker of response to anti-PD-L1 immunotherapy50, we next investigate whether the levels of DHA and PD-L1 in clinical tumor samples were related to a therapeutic response. The gene discussed is CD274; the disease is neoplasm.